Stock listing
BOATS:GCTK GlucoTrack, Inc. Stock
US listing (BOATS) of GlucoTrack, Inc. · home listing NASDAQ:GCTK
Follow GlucoTrack, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GCTK
$0.183 USD -0.004 (-2.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GCTK
- Day range
- $0.183 – $0.200 USDNov 20, 2026
- Volume
- 10,329 sharesNov 20, 2026
- Market cap
- $217,049 USDAt the close on Nov 20, 2026 · price × 1.18M shares outstanding
- 52-week range
- $0.183 – $207.000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.58M USDMedian day 25,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GCTK · Home | $0.183 USD | -0.004 (-2.0%) | 10,329 | $0.187 | $0.200 | $0.183 | $0.187 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GCTK · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.183 | -0.004 | -2.0% | $0.187 | $0.200 | $0.183 | 10,329 | |
| $0.187 | 0.000 | 0.0% | $0.187 | $0.187 | $0.187 | 403 | |
| $0.187 | -0.003 | -1.6% | $0.187 | $0.187 | $0.187 | 2,237 | |
| $0.190 | -0.027 | -12.4% | $0.210 | $0.230 | $0.190 | 7,554 | |
| $0.217 | -0.023 | -9.7% | $0.240 | $0.240 | $0.217 | 7,384 | |
| $0.240 | -0.040 | -14.3% | $0.270 | $0.290 | $0.227 | 11,724 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.340 | $0.280 | 11,227 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.370 | $0.280 | 13,923 | |
| $0.280 | -0.020 | -6.7% | $0.280 | $0.340 | $0.280 | 4,830 | |
| $0.300 | -0.080 | -21.1% | $0.380 | $0.380 | $0.300 | 41,300 | |
| $0.380 | -0.020 | -5.0% | $0.400 | $0.420 | $0.365 | 39,100 | |
| $0.400 | -0.058 | -12.7% | $0.400 | $0.465 | $0.400 | 20,300 | |
| $0.458 | -0.032 | -6.5% | $0.487 | $0.487 | $0.342 | 110,500 | |
| $0.490 | -0.320 | -39.5% | $0.760 | $0.760 | $0.490 | 132,400 | |
| $0.810 | -0.580 | -41.7% | $0.530 | $0.910 | $0.500 | 553,100 | |
| $1.390 | -0.660 | -32.2% | $2.000 | $2.240 | $1.070 | 5,470,200 | |
| $2.050 | +0.340 | +19.9% | $2.000 | $2.500 | $1.800 | 28,294,200 | |
| $1.710 | +0.100 | +6.2% | $1.530 | $1.760 | $1.290 | 4,718,200 | |
| $1.610 | +0.804 | +99.8% | $0.840 | $1.760 | $0.777 | 34,499,300 | |
| $0.806 | -0.392 | -32.7% | $1.180 | $1.240 | $0.746 | 180,700 | |
| $1.198 | -0.080 | -6.3% | $1.218 | $1.310 | $1.120 | 36,175 | |
| $1.278 | -0.024 | -1.8% | $1.324 | $1.350 | $1.254 | 18,550 | |
| $1.302 | -0.068 | -5.0% | $1.354 | $1.356 | $1.180 | 12,700 | |
| $1.370 | -0.080 | -5.5% | $1.476 | $1.476 | $1.364 | 25,700 | |
| $1.450 | -0.214 | -12.9% | $1.680 | $1.680 | $1.408 | 36,100 | |
| $1.664 | -0.110 | -6.2% | $1.760 | $1.760 | $1.520 | 38,450 | |
| $1.774 | -0.446 | -20.1% | $2.200 | $2.200 | $1.722 | 88,575 | |
| $2.220 | -0.100 | -4.3% | $2.320 | $2.320 | $2.140 | 40,525 | |
| $2.320 | +0.260 | +12.6% | $2.180 | $2.400 | $2.080 | 78,925 | |
| $2.060 | -0.160 | -7.2% | $2.240 | $2.240 | $2.000 | 58,950 | |
| $2.220 | -0.080 | -3.5% | $2.240 | $2.420 | $2.160 | 52,150 | |
| $2.300 | +0.040 | +1.8% | $2.240 | $2.320 | $2.200 | 24,300 | |
| $2.260 | +0.040 | +1.8% | $2.240 | $2.280 | $2.140 | 42,000 | |
| $2.220 | -0.200 | -8.3% | $2.320 | $2.404 | $2.180 | 58,200 | |
| $2.420 | -0.400 | -14.2% | $2.680 | $2.680 | $2.300 | 73,300 | |
| $2.820 | -0.460 | -14.0% | $3.280 | $3.280 | $2.760 | 158,525 | |
| $3.280 | -0.200 | -5.7% | $3.580 | $3.640 | $3.020 | 293,075 | |
| $3.480 | -0.120 | -3.3% | $3.440 | $3.700 | $3.140 | 66,200 | |
| $3.600 | -0.040 | -1.1% | $3.680 | $3.900 | $3.560 | 129,925 | |
| $3.640 | -1.520 | -29.5% | $4.620 | $4.720 | $3.540 | 505,850 | |
| $5.160 | +1.100 | +27.1% | $4.860 | $6.500 | $4.760 | 12,900,075 | |
| $4.060 | -0.380 | -8.6% | $4.460 | $4.540 | $3.996 | 6,894,675 | |
| $4.440 | -0.160 | -3.5% | $4.440 | $4.620 | $4.420 | 135,000 | |
| $4.600 | -0.340 | -6.9% | $5.020 | $5.020 | $4.420 | 9,675 | |
| $4.940 | +0.180 | +3.8% | $4.780 | $5.100 | $4.780 | 6,925 | |
| $4.760 | +0.270 | +6.0% | $4.560 | $4.800 | $4.480 | 4,675 | |
| $4.490 | -0.050 | -1.1% | $4.500 | $4.680 | $4.360 | 15,125 | |
| $4.540 | -0.360 | -7.3% | $4.820 | $4.820 | $4.440 | 14,150 | |
| $4.900 | -0.200 | -3.9% | $5.000 | $5.340 | $4.620 | 37,925 | |
| $5.100 | -1.360 | -21.1% | $6.120 | $6.120 | $4.520 | 185,425 | |
| $6.460 | +0.180 | +2.9% | $6.080 | $6.460 | $6.080 | 4,350 | |
| $6.280 | +0.420 | +7.2% | $5.860 | $6.600 | $5.860 | 14,725 | |
| $5.860 | -0.100 | -1.7% | $6.060 | $6.220 | $5.800 | 8,925 | |
| $5.960 | -0.680 | -10.2% | $6.520 | $6.620 | $5.900 | 18,050 | |
| $6.640 | -0.420 | -5.9% | $7.120 | $7.292 | $6.580 | 11,875 | |
| $7.060 | -0.300 | -4.1% | $6.980 | $7.960 | $6.980 | 14,925 | |
| $7.360 | -1.140 | -13.4% | $8.160 | $8.540 | $7.350 | 19,375 | |
| $8.500 | +0.040 | +0.5% | $8.400 | $8.720 | $8.000 | 38,275 | |
| $8.460 | -0.120 | -1.4% | $8.400 | $8.670 | $8.370 | 2,978 | |
| $8.580 | -1.050 | -10.9% | $10.050 | $10.050 | $8.490 | 1,881 | |
| $9.630 | -0.570 | -5.6% | $10.320 | $10.500 | $9.450 | 634 | |
| $10.200 | +0.240 | +2.4% | $10.200 | $10.200 | $9.900 | 621 | |
| $9.960 | -0.450 | -4.3% | $10.110 | $10.350 | $9.900 | 245 | |
| $10.410 | +0.150 | +1.5% | $10.140 | $11.100 | $9.900 | 767 | |
| $10.260 | -0.210 | -2.0% | $10.410 | $10.500 | $9.900 | 592 |
Splits
6 splits since 2021 · NASDAQ:GCTK · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-2 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-60 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-5 | Consolidation | |
| 1-for-13 | Consolidation |
- Ticker
- BOATS:GCTK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 22, 2026
Glucotrack, Inc. Announces Reverse Stock Split
Latest deck · Apr 30, 2026
Investor Presentation (April 2026)
Investor deck · 23 slides
Latest news
Glucotrack, Inc. Announces Reverse Stock Split
Oct 22, 2026
Closed $1.20 (-6.3%) on Oct 22, 2026
Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications
Oct 14, 2026
Closed $1.77 (-20.1%) on Oct 14, 2026
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Sep 24, 2026
Closed $5.16 (+27.1%) on Sep 24, 2026
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
Sep 23, 2026
Closed $4.06 (-8.6%) on Sep 23, 2026
Glucotrack Announces $11.5 Million Financing
Sep 11, 2026
Closed $5.10 (-21.1%) on Sep 11, 2026
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
Aug 17, 2026
Closed $10.26 (-6.8%) on Aug 17, 2026
E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
Aug 6, 2026
Closed $14.16 (-10.1%) on Aug 6, 2026
Issued by another party
Glucotrack Announces $5.5 Million Financing
Aug 5, 2026
Closed $15.75 (-12.4%) on Aug 5, 2026
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
Jul 31, 2026
Closed $14.31 (-38.8%) on Jul 31, 2026
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
Jul 29, 2026
Closed $23.40 (+173.7%) on Jul 30, 2026
GlucoTrack, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 108 in all · newest Oct 22, 2026 · oldest 2021
- Decks
- 11 decks · latest Apr 30, 2026
Where GlucoTrack, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GCTK · Home listing | NASDAQ | United States | USD |
| BOATS:GCTK · This page | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$887,951 USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.73
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,522 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| Median of the others | US$278,926 | US$73,510 | 1.2× | 0.3× | 0.1× | −262.8% | 0.0× | 1.14 |
Team and board
Officers
| Officer | Role |
|---|---|
| Paul V. Goode | President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Erin Carter | Chair of the Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 | −22.6% |
| Q2 2026 | Aug 14, 2026 | −6.6% |
| Q3 2025 | Nov 13, 2025 | −12.6% |
| Q2 2025 | Aug 14, 2025 | −0.5% |
| Q1 2025 | May 14, 2025 | +2.7% |
| Q4 2024 | Mar 31, 2025 | +9.8% |
| Q4 2022 | Mar 31, 2023 | +15.4% |
| Q3 2022 | Nov 14, 2022 | −4.0% |
| Q2 2022 | Aug 15, 2022 | +8.4% |
| Q1 2022 | May 16, 2022 | +6.0% |
All 14 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2021 | Mar 31, 2022 | −3.0% |
| Q3 2021 | Nov 15, 2021 | +2.6% |
| Quarter to Jun 30, 2021 | Aug 16, 2021 | −6.0% |
| Quarter to Mar 31, 2021 | Apr 13, 2021 | −20.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 23 slides | Apr 30, 2026 |
| Investor Presentation (April 2026) | Investor deck | 23 slides | April 2026 |
| Investor Presentation (December 2025) | Investor deck | 25 slides | December 2025 |
| Investor Presentation (May 2025) | Investor deck | 25 slides | May 2025 |
| Investor Presentation (February 2025) | Investor deck | 17 slides | February 2025 |
| Investor Presentation (August 2024) | Investor deck | 28 slides | Aug 26, 2024 |
| Investor Presentation (July 2024) | Investor deck | 28 slides | Jul 8, 2024 |
| Investor Presentation (January 2024) | Investor deck | 24 slides | January 2024 |
| Integrity Applications — Investor Presentation (November 2017) | Investor deck | 22 slides | Nov 3, 2017 |
| Integrity Applications — Investor Presentation (October 2017) | Investor deck | 16 slides | Oct 5, 2017 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Integrity Applications — AMIZINO Fall 2013 Small Cap / Micro Cap Investment Conference | Conference | 28 slides | Oct 29, 2013 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$3.1M · US$2.04 a share · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) | Sep 24, 2026 |
| Convertible notes with warrants Announced: about US$11.5M · Warrants at US$7.5 · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) | Sep 11, 2026 |
| Private placement of units Announced: US$2M · US$0.75 a unit · Warrants at US$1.5 for 60 months · E.F. Hutton & Co. Dealers: E.F. Hutton & Co. Use of proceeds: Strengthen the balance sheet and provide additional growth capital | Aug 5, 2026 |
| Convertible debt Announced: US$3.5M · E.F. Hutton & Co. Dealers: E.F. Hutton & Co. Use of proceeds: Strengthen the balance sheet and provide additional growth capital | Aug 5, 2026 |
| Bridge financing (securities not stated) Closed: E.F. Hutton & Co. Dealers: E.F. Hutton & Co. (lead) Use of proceeds: Support strategic growth, including advancing the combined Glucotrack-Lokahi platform and other capital markets activities | Jul 17, 2026 |
| Private placement of private placement financing (securities not stated) Update: private placement Use of proceeds: Strengthen the combined company's capital position and near-term execution; part to fund Glucotrack's legacy CBGM technology in a dedicated subsidiary | Jul 16, 2026 |
| Private placement of shares of common stock (or common stock equivalents) and warrants Announced: about US$4M · US$3.87 a share · Warrants at US$3.87 for 60 months · Curvature Securities LLC Dealers: Curvature Securities LLC (lead) Use of proceeds: Working capital and general corporate purposes | Dec 30, 2025 |
| Common stock under equity purchase agreement Update: US$20M Buyers: Sixth Borough Capital Fund; Sixth Borough Capital Fund LP | Nov 3, 2025 |
| Public offering of shares of common stock Announced: about US$3M · US$1.15 a share · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) | Feb 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 70.8K | 208.0K | 17.0B | 589.5K | 611.7K |
| Cost of revenue | 36.0K | 13.0K | 23.0K | 42.0K | 47.0K | 51.0K | 95.6K | 140.2K | 59.6K | |
| Gross profit | -36.0K | -13.0K | -23.0K | -42.0K | -47.0K | 208.0K | -52.1K | 449.3K | 552.1K | |
| Research and development | 9.81M | 9.50M | 4.70M | 1.97M | 1.81M | 1.53M | 1.61M | 3.03M | 3.21M | 2.88M |
| Selling, general and administrative | 6.28M | 4.66M | 2.27M | 2.45M | 139.0K | 415.0K | 1.49M | 3.48M | 1.53M | 1.13M |
| Operating income | -16.1M | -14.5M | -7.10M | -4.43M | -4.04M | -3.13M | 3.51M | -6.54M | 10.6M | -5.66M |
| Depreciation and amortization | 42.0K | 36.0K | 13.0K | 23.0K | 32.0K | 32.0K | 51.0K | 58.8K | 67.9K | 59.6K |
| EBITDA | -16.0M | -14.5M | -7.09M | -4.41M | -4.01M | -3.10M | 3.56M | -6.48M | 10.6M | -5.60M |
| Interest expense | 44.0K | 0 | 3.00K | 4.16M | 98.0K | 10.0K | 18.3K | 24.4K | 16.2K | |
| Income before tax | -19.4M | -22.6M | -7.10M | -4.43M | -4.07M | -2.70M | -3.52M | -6.72M | -10.3M | -5.41M |
| Income tax | 22.6M | 855.0K | 3.00K | 33.0K | -98.0K | 43 | -13.2M | 24.4K | 16.2K | |
| Net income | -19.4M | -22.6M | -7.10M | -4.43M | -4.07M | -2.70M | 3.52M | -6.72M | 10.3M | -5.41M |
| Earnings per share, basic | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 | -0.02 | -0.02 | -4.74 | -1.87 | -1.08 |
| Earnings per share, diluted | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 | 0.19 | -0.02 | -4.74 | -1.87 | -1.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M | 9.82M | 419.0K | 97.1K | 53.8K | 148.8K |
| Receivables | 0 | 66.0K | 70.0K | 22.8K | 121.8K | 92.1K | ||||
| Inventory | 0 | 284.0K | 184.0K | 171.0K | 957.3K | 1.42M | ||||
| Current assets | 7.67M | 5.77M | 4.87M | 2.38M | 6.11M | 10.2M | 718.0K | 314.1K | 1.23M | 2.02M |
| Property, plant and equipment | 138.0K | 95.0K | 27.0K | 40.0K | 69.0K | 149.0K | 134.0K | 149.8K | 216.7K | 240.5K |
| Total assets | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M | 10.6M | 1.10M | 688.2K | 1.67M | 2.46M |
| Accounts payable | 1.32M | 992.0K | 839.0K | 672.0K | 631.0K | 869.0K | 1.53M | 2.06M | 2.42M | 1.63M |
| Current liabilities | 4.77M | 1.27M | 1.51M | 1.01M | 883.0K | 1.34M | 2.27M | 3.22M | 3.69M | 2.35M |
| Long-term debt | 231.0K | 203.0K | 196.0K | 195.0K | 210.0K | 197.0K | 190.4K | 168.2K | ||
| Total debt | 33.0K | 267.0K | 196.0K | 195.0K | 250.0K | 363.0K | 378.0K | 168.2K | 182.8K | 162.0K |
| Total liabilities | 5.01M | 18.9M | 1.71M | 1.21M | 1.11M | 1.62M | 2.51M | 3.56M | 4.82M | 3.37M |
| Shareholders' equity | 2.83M | -13.0M | 3.20M | 1.23M | 5.16M | 8.98M | -1.41M | -2.87M | -16.6M | -10.9M |
| Shares outstanding | 910.7K | 13.4K | 208.9K | 15.5M | 15.5M | 15.4M | 161.9M | 141.6M | 6.82M | 6.03M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.2M | -12.5M | -6.56M | -3.73M | -3.77M | -3.50M | -3.90M | -4.89M | -5.90M | -5.31M |
| Capital spending | -96.0K | -104.0K | 0 | -1.00K | -5.00K | -53.0K | -23.0K | -5.37K | -19.5K | -76.5K |
| Free cash flow | -15.3M | -12.6M | -6.56M | -3.73M | -3.77M | -3.55M | -3.92M | -4.90M | -5.91M | -5.39M |
| Cash from investing | -96.0K | -104.0K | 1.00K | -1.00K | -53.0K | -23.0K | -5.37K | -19.5K | -76.5K | |
| Cash from financing | 17.0M | 13.7M | 8.73M | 0 | 0 | 13.0M | 4.20M | 4.96M | 5.75M | 4.94M |
| Dividends paid | 0 | -5.73K | -13.5K | |||||||
| Change in cash | 1.76M | 1.13M | 2.17M | -3.78M | -3.77M | 9.41M | 326.0K | 56.3K | -91.2K | -459.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| NT 10-Q · Late filing notice | Nov 16, 2026 | Explanation request | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| 8-K · Current report | Oct 22, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Oct 14, 2026 | Meeting notice | SEC |
| S-1/A · Registration statement, amended | Oct 13, 2026 | Offer document | SEC |
| 425 | Oct 13, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Oct 13, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 24, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2026 | Material contract | SEC |
| 425 | Sep 23, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| 8-K · Current report | Sep 18, 2026 | Management or board change | SEC |
| S-1 · Registration statement | Sep 17, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 14, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 11, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 425 | Aug 28, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 28, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 19, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Aug 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 5, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Jul 31, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Jul 29, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 27, 2026 | Material contract | SEC |
| DRS · Draft registration statement | Jul 24, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Jul 17, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 17, 2026 | Meeting notice | SEC |
| 425 | Jul 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 15, 2026 | Acquisition or disposal | SEC |
| PRE 14A · Preliminary proxy statement | Jun 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 7, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| POS AM · Amendment to an effective registration | Apr 29, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 14, 2026 | Material contract | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 8-K · Current report | Mar 27, 2026 | Current report | SEC |
| 8-K · Current report | Mar 13, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Feb 9, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 29, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 28, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 13, 2026 | Offer document | SEC |
| 8-K · Current report | Dec 31, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 7, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Nov 6, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 31, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 28, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 15, 2025 | Meeting notice | SEC |
| S-1/A · Registration statement, amended | Oct 8, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Oct 3, 2025 | Meeting notice | SEC |
| S-1 · Registration statement | Sep 29, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Sep 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 12, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 11, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Sep 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Jul 25, 2025 | Current report | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| 8-K · Current report | May 23, 2025 | Management or board change | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| 8-K · Current report | Apr 3, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 8-K · Current report | Mar 13, 2025 | Financing | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Feb 7, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 5, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Jan 14, 2025 | Financing | SEC |
| 8-K · Current report | Jan 13, 2025 | Financing | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 8-K · Current report | Jan 7, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 31, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 17, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 17, 2024 | Material contract | SEC |
| DEF 14A · Proxy statement | Dec 6, 2024 | Meeting notice | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Nov 22, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Nov 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 14, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 424B4 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 12, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 8, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Nov 8, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Nov 4, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Oct 24, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 4, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Oct 1, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 30, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 27, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 26, 2024 | Meeting outcome | SEC |
| S-3 · Registration statement | Sep 23, 2024 | Offer document | SEC |
| S-1 · Registration statement | Sep 16, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2024 | Financing | SEC |
| SC 13G · Big-stake notice | Sep 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 3, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 27, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Aug 19, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Aug 16, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 9, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 8-K · Current report | Jul 31, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 22, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 13, 2024 | Current report | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| 8-K · Current report | May 16, 2024 | Current report | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| D | May 8, 2024 | Other filings | SEC |
| 8-K · Current report | May 2, 2024 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Apr 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2024 | Insider trade | SEC |
| DEF 14A · Proxy statement | Apr 1, 2024 | Meeting notice | SEC |
This page holds 200 of 497 filings. Open Filings
Cap table
Built by 6ix from GlucoTrack, Inc.’s releases · as of Sep 24, 2026
- Common shares
- 1,184,119
- Fully diluted
- 1,184,119
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,184,119 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,184,119 |
| Oct 22, 2026 | |
| Aug 27, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James S Cardwell Other companies: Esports Entertainment Group, Inc. (Interim CFO · Feb 20, 2020 – Feb 20, 2020 · Past); VerifyMe, Inc. (Chief Financial Officer · Jan 11, 2018 – Jan 11, 2018 · Past) | Chief Financial Officer · Oct 11, 2023 – Oct 11, 2023 · Past |
| Peter C. Wulff Other companies: PURE Bioscience (CFO, COO & Secretary · Nov 5, 2012 – Oct 23, 2013 · Past); Alphatec Holdings, Inc. (CFO, VP and Treasurer · Jun 16, 2008 – Aug 10, 2010 · Past) | Chief Financial Officer · Jan 28, 2025 – Nov 5, 2026 · Past |
| Andrew K Balo Other companies: DexCom, Inc. (EVP Regulatory Strategy Clinic · May 2, 2006 – Mar 10, 2023 · Past) | Director · Jun 14, 2024 – Mar 26, 2025 · Past |
| Brendel Victoria Carr Other companies: Vicarious Surgical, Inc. (Director · Jan 23, 2023 – Jun 10, 2024 · Past) | Director · May 22, 2025 – May 22, 2025 · Past |
| Allen Danzig | Director · Mar 28, 2025 – Mar 28, 2025 · Past |
| Avner Gal | Chairman and CEO, Director · Aug 14, 2012 – Mar 11, 2015 · Past |
| David Malka | Vice President of Operations · Aug 14, 2012 – Apr 13, 2017 · Past |
| david podwalski | Chief Commercial Officer · Jun 26, 2017 – Jun 26, 2017 · Past |
| Drew Sycoff | Director · Apr 22, 2024 – Jul 1, 2024 · Past |
| Eran Hertz | Chief Financial Officer · Nov 17, 2013 – Sep 30, 2014 · Past |
All 19 people
| Person | Seat |
|---|---|
| Erin Carter | Chair of the Audit Committee · Since at least Aug 25, 2023 |
| John A Graham | Chief Executive Officer, Director · Mar 20, 2017 – Mar 20, 2017 · Past |
| John Ballantyne | Director · Jul 30, 2024 – Aug 16, 2024 · Past |
| Leslie Seff | Director · Mar 23, 2016 – Jun 1, 2017 · Past |
| Luis Malave | Director · Mar 25, 2025 – Mar 31, 2025 · Past |
| Paul V. Goode | President and Chief Executive Officer · Since at least Apr 22, 2024 |
| Robert Fischell | Director · Aug 14, 2012 – Mar 28, 2025 · Past |
| Sami Sassoun | Chief Financial Officer · Jan 31, 2017 – Jan 31, 2017 · Past |
| Zvi Cohen | Director · Aug 14, 2012 – Mar 11, 2015 · Past |
Log in to ask 6ix AI your own questions about GlucoTrack, Inc.